HealthExperts urge PBS funding for drug used to treat breast cancer, endometriosis and gender dysphoria

Australia’s Pharmaceutical Benefits Advisory Committee has recommended unrestricted PBS funding for triptorelin, after AstraZeneca said it would withdraw Zoladex, potentially leaving more than 7,500 women with breast cancer without an alternative. If adopted, the listing would fund gender-affirming care through the PBS for the first time.

Australiatriptorelinbreast cancergender-affirming care

TThe Guardian★★★☆☆2026-08-18 15:00Original